Abstract
There are many chemotherapeutic interventions available for tuberculosis (TB) and are in use for more than five decades, but still there is an urgent need for novel drugs against new targets due to emergence of resistant strains. Moreover, the ability of Mycobacterium tuberculosis (Mtb) to survive within granulomas in a non-replicating latent stage prolongs the course of drug dose and hence increases the severity of the disease. The significant rerouting of metabolism is one of the key processes that help mycobacteria adapt to the hostile environment of host granuloma. In this review, we are focusing on some of the cofactor biosynthetic pathways of Mycobacterium tuberculosis and their utilization as drug targets.
Current Respiratory Medicine Reviews
Title:Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets
Volume: 10 Issue: 2
Author(s): Shilpika Pandey, Sarthak Gaur, Neha Topno, Sidharth Chopra and Arunava Dasgupta
Affiliation:
Keywords: FAD, Mtb, NAD, Pantothenate, iron, vitamin.
Abstract: There are many chemotherapeutic interventions available for tuberculosis (TB) and are in use for more than five decades, but still there is an urgent need for novel drugs against new targets due to emergence of resistant strains. Moreover, the ability of Mycobacterium tuberculosis (Mtb) to survive within granulomas in a non-replicating latent stage prolongs the course of drug dose and hence increases the severity of the disease. The significant rerouting of metabolism is one of the key processes that help mycobacteria adapt to the hostile environment of host granuloma. In this review, we are focusing on some of the cofactor biosynthetic pathways of Mycobacterium tuberculosis and their utilization as drug targets.
Export Options
About this article
Cite this article as:
Pandey Shilpika, Gaur Sarthak, Topno Neha, Chopra Sidharth and Dasgupta Arunava, Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets, Current Respiratory Medicine Reviews 2014; 10 (2) . https://dx.doi.org/10.2174/1573398X10666140822004506
DOI https://dx.doi.org/10.2174/1573398X10666140822004506 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies The Potential of Ganoderma Lucidum as Antimicrobial Agent for Multidrug- Resistant Mycobacterium Tuberculosis
Anti-Infective Agents Spices Chemoconstituents as Persuasive Inhibitor of S. typhimurium Virulent Protein L-asparaginase
Letters in Drug Design & Discovery New Tuberculostatic Agents Targeting Nucleic Acid Biosynthesis: Drug Design using QSAR Approaches
Current Pharmaceutical Design Macrolide Resistance in Mycobacteria
Medicinal Chemistry Reviews - Online (Discontinued) Particulate and Vesicular Drug Carriers in the Management of Tuberculosis
Current Drug Delivery Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride
Anti-Infective Agents Computational Biology and Drug Discovery: From Single-Target to Network Drugs
Current Bioinformatics Editorial (Thematic Issue: Polypharmacology in Drug Discovery)
Current Pharmaceutical Design Structure-and-Mechanism-Based Design and Discovery of Type II Mycobacterium Tuberculosis Dehydroquinate Dehydratase Inhibitors
Current Topics in Medicinal Chemistry Ethnobotanical Bioprospection of Candidates for Potential Antimicrobial Drugs from Brazilian Plants: State of Art and Perspectives
Current Protein & Peptide Science Chemical Constituents and Biological Activities of Simira Genus: A Contribution to the Chemotaxonomic of Rubiaceae Family
The Natural Products Journal Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis
Current Drug Metabolism On the Paradigm Shift Towards Multitarget Selective Drug Design
Current Computer-Aided Drug Design Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Mucosal Adjuvants
Current Pharmaceutical Design Synthesis and Biological Evaluation of 3΄-C-Ethynyl and 3΄-C-(1,4-disubstituted-1,2,3-triazolo) Double-Headed Pyranonucleosides
Medicinal Chemistry MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules
Current Medicinal Chemistry <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Assessing and Treating Cognitive Impairment in Schizophrenia: Current and Future
Current Pharmaceutical Design